CYTEK BIOSCIENCES INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect our two Class I director nominees, each to serve a three-year term, expiring at our 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal: Deborah Neff

CYTEK BIOSCIENCES INC.’s own tally for this item (“Elect Director: Deborah Neff”): 33,819,367 for, 48,183,714 withheld, per its Form 8-K filed June 24, 2025 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 41% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 7,060,272 for, 13,721,242 withheld, 13,413,653 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: To elect our two Class I director nominees, each to serve a three-year term, expiring at our 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal: Richard Chin, M.D.

CYTEK BIOSCIENCES INC.’s own tally for this item (“Elect Director: Richard Chin, MD”): 81,794,582 for, 208,499 withheld, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 34,191,253 for, 3,912 withheld, 0 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS FOR THE YEAR ENDED DECEMBER 31, 2024, AS SET FORTH IN OUR PROXY STATEMENT.

CYTEK BIOSCIENCES INC.’s own tally for this item (“2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2024”): 76,368,883 for, 5,630,057 against — passed, per its Form 8-K filed June 24, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2024 was approved based on the following results of voting:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 60 managers: 31,926,211 for, 2,324,428 against, 0 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 123 managers: 29,882,819 for, 4,102,672 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

CYTEK BIOSCIENCES INC.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December”): 95,862,612 for, 7,657,004 against — passed, per its Form 8-K filed June 24, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified based on the following results of voting:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 34,157,430 for, 37,736 against, 0 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.